 NEW YORK and SAN DIEGO, July 01, 2021 GLOBE NEWSWIRE -- Zentalis Pharmaceuticals, Inc. Nasdaq: ZNTL, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of an underwritten public offering of 3,565,000 shares of its common stock at a public offering price of 48.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 465,000 additional shares. The total gross proceeds for the offering are approximately 172.9 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. 